PharmaMar Has Requested The Process Of Re-Examination For Aplidin From The EMA
Madrid, Spain (Press Release) – PharmaMar (MCE: PHM) has announced the initiation of the re-examination process by the European Medicines Agency (EMA) for Aplidin® (plitidepsin) for the indication of relapsed and refractory multiple myeloma.
PharmaMar believes that this novel molecule could become part of the therapeutic arsenal available for the treatment of multiple myeloma in Europe.
It is worth noting that the re-examination procedure is handled by the EMA´s CHMP and usually lasts around 4 months. It concludes with either the confirmation of the negative opinion or with the issuing of a new positive opinion by the CHMP.
After finalizing this process of re-examination, the European Commission will be in charge of emitting the final verdict on the Marketing Authorization Application (MAA) for Aplidin® (plitidepsin), which could arrive around June or July, 2018.
Source: PharmaMar.
Related Press Releases:
- World-First Approval For Multiple Myeloma Drug Aplidin
- CARsgen Therapeutics Receives Positive EMA Opinion On Orphan Drug Designation For Fully Human Anti-BCMA CAR-T Cells (CT053) For The Treatment Of Multiple Myeloma
- CHMP Issues Positive Opinion On Split Dosing Regimen For Darzalex (Daratumumab)
- CHMP Issues Positive Opinion Recommending Darzalex (Daratumumab) For Front Line Multiple Myeloma
- Cytori Files Pre-Submission Request For New Drug Application
